Funding Opportunities

Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.

Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission

Open Date (Earliest Submission Date): February 05, 2023

Expiration Date: January 08, 2026

The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.

For more information click here

Contract Solicitation: Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA)

The purpose of the proposed contract will be to provide a Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA), a resource to: (1) support the ability of laboratories (Labs) to reliably perform study-specified MTB tests; (2) evaluate MTB technologies and specimen processes for use in clinical investigations; and (3) disseminate technical and scientific data.

Notice ID: 75N93022R00015

  • Original Published Date: Aug 31, 2022 08:19 am EDT
  • Original Date Offers Due: Nov 30, 2022 03:00 pm EST

For more info, click here

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)

Open Date (Earliest Submission Date): April 01, 2023

Expiration Date: May 02, 2025

This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS research related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere. Projects must be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been described most recently in NOT-OD-20-018.

For more information click here

Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01, Clinical Trial Not Allowed)

Open Date (Earliest Submission Date): November 07, 2022

Expiration Date: December 08, 2024

The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and their effect on immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection to identify immune targets for development of host-directed therapies.

For more information click here

TB Centers of Excellence - Grants Notice

TB Centers of Excellence for Training, Education and Medical Consultation (COE)

CDC plans to establish and fund up to four regionally-assigned Tuberculosis Centers of Excellence (TB COE) to facilitate efforts to prevent, treat, and control TB disease and latent TB infection (LTBI) in the United States (U.S.). The TB COE will focus on two major activities: (1) increasing knowledge, skills, and abilities for TB prevention and control through communication, education, and training activities, and; (2) improving sustainable evidence based TB clinical practices and patient care through the provision of expert medical consultation. The funds available for these core activities will be used to support TB and LTBI communication efforts, training, education, and medical consultation activities.

Funding Organization

Centers for Disease Control and Prevention - NCHHSTP

Closing Date for Applications

September 6th, 2022

 

For more information, https://www.grants.gov/web/grants/view-opportunity.html?oppId=336618

TB Elimination Alliance Announces 2022-2023 Mini-Grant Program

The Tuberculosis (TB) Elimination Alliance (TEA) is offering Mini-Grants to organizations serving Asian American (AA), Native Hawaiian, and Pacific Islander (NH/PI) communities that are disproportionately impacted by latent TB infection (LTBI) and/or TB. Additional preference is given to organizations currently serving Asian/Asian American (A/AA) and NH/PI populations with an interest in expanding to non-US born Latino American, and US born African American communities.

Mini-Grant proposals must align with TEA’s priority areas and activities that reflect community engagement and education, provider education, and/or quality improvement.

Up to 15 awards will be provided to selected organizations. Each award amount will be between $10,000 and $30,000. Deadline to apply is Friday, August 5 by 5:00pm local time.

For more information please visit, https://tbeliminationalliance.org/2022-2023-tb-elimination-alliance-mini-grant-program-request-for-funding-proposal/

NIAID June 2022 Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. Concepts reveal possible initiatives or give you ideas for an investigator-initiated application.

 

Analyzing Early Events in Tuberculosis (TB) and TB/HIV Infection To Identify Interventional Targets

Request for Applications—proposed FY 2024 initiative

Objective: Early events associated with Mycobacterium tuberculosis (Mtb) infection are not well understood. However, studies delineating the initial stage of Mtb infection may identify unique targets for more effective vaccine adjuvants and immunomodulators, as well as improved biomarkers to advance prevention and therapy of TB. The objectives of this initiative are to better understand how Mtb evades and disrupts host immunity at the earliest stages of infection, and how myeloid (macrophages, dendritic cells, eosinophils), lymphoid (T cells, B cells, innate lymphoid cells) and non-immune cells (alveolar epithelial cells, pneumocytes, vascular) in the airway and lung interact with Mtb and each other. Furthermore, delineating the effects of HIV co-infection on immune mechanisms during early Mtb infection will facilitate the development of effective immune-based interventions for people living with HIV.

Contact: 
Robert Mahon
robert.mahon@nih.gov

 


Consortium for Design of TB Drug Regimens

Request for Applications—proposed FY 2024 initiative

Objective: To establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models with clinical data and identify the most efficacious combination regimens for future clinical testing to optimize relapse-free TB treatment.

Contact:
Barbara Laughon
blaughon@mail.nih.gov


Mycobacterium tuberculosis Quality Assessment (TBQA) Program

Request for Proposals—proposed FY 2024 initiative

Objective: TBQA will 1) support the ability of laboratories to reliably perform study-specified Mycobacterium tuberculosis (Mtb) tests; 2) evaluate Mtb technologies and specimen processes for use in clinical investigations; 3) disseminate technical and scientific data; 4) perform late-stage assay validation and/or Mtb assay testing of clinical samples in a CLIA-certified laboratory (Option); and 5) support public health emergency needs (Option). The TBQA will serve NIAID-sponsored and collaborating clinical trial networks and cohorts as well as individual grantees conducting research in and outside the United States. Examples of NIAID-sponsored Networks include the Adult AIDS Clinical Trials Group (ACTG), the International Maternal Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT), and the HIV Vaccine Trials Network (HVTN). Examples of NIAID-sponsored TB cohorts include the India and Brazil Regional Prospective Observational Research for Tuberculosis (RePORT).

Contact: 
Isaac Elliott
isaac.elliott@nih.gov

 

You can find more information here

 

Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP), due September 07, 2022

Open Date (Earliest Submission Date): September 07, 2022

Expiration Date: May 08, 2025

The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.

This Notice also encourages applications to develop once-a-month SR/LA strategies for treatment of latent TB and hepatitis B

https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-042.html?utm…

January 2022 DAIDS Council-Approved Concepts

Notice of Special Interest (NOSI)—Identifying Immune Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection

Notice of Special Interest—proposed FY 2023 initiative

Contact:
Josh Radke
josh.radke@nih.gov

Objective: NIAID has a specific interest in research toward understanding the role cell death mechanisms (CDMs) play in response to Mycobacterium tuberculosis (Mtb) infection, how Mtb subverts cell death pathways to promote infection, and to identify cellular targets that could be exploited as potential host-directed therapies to treat Mtb and Mtb/HIV co-infection.

https://www.niaid.nih.gov/grants-contracts/january-2022-daids-council-approved-concepts#05

Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed), due 06/08/2022

Open Date (Earliest Submission Date): May 08, 2022

Expiration Date: June 09, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-015.html